Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

IRVINE, CA--(Marketwired - May 26, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts. As the world's largest customer, the U.S. Federal Government issues over $192 billion in contracts and over $450 billion in grants annually.

Cannabis Science has completed its registration in the U.S. Government's System for Award Management (SAM), and has applied for and received a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency's CAGE Program Office at the U.S. Department of Defense. Cannabis Science is now listed with all U.S. companies eligible for Federal Government Contracts. "Achieving eligibility to access contracting opportunities with the U.S. Federal Government is a significant step for Cannabis Science," stated Mr. Raymond C. Dabney, Cannabis Science's President, CEO, and Co-founder. "I believe we can leverage the unique experience and expertise of our company to win new business and grow Cannabis Science's revenue base. We also plan to work closely with our strategic partners and collaborators to access Federal contracting and grant opportunities."

Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:

§ 541711 - Research and Development In Biotechnology
§ 621511 - Medical Laboratories
§ 624230 - Emergency and Other Relief Services

SAM is the primary vendor database for the U.S. Federal Government. Having vendor information immediately available allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, research & development projects, and particular supply needs, as well as for pandemic alert and other emergency requirements.

Cannabis Science intends to explore funding opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others.

As part of its mandate to study drug abuse and addiction and other health effects of both legal and illegal drugs, NIDA funds a wide range of research on marijuana (cannabis); its main psychotropic ingredient, delta-9-tetrahydrocannabinol (THC); and chemicals related to THC (cannabinoids). Research suggests that THC and other cannabinoids may have potential in the treatment of pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions. NIDA has provided and continues to provide funding for research related to therapeutic uses of cannabinoids as it pertains to its mission, including studies on the use of THC and cannabidiol (CBD), another chemical constituent of marijuana, for the treatment of pain (as an alternative to opioid pain relievers), addiction, and other disorders. Research on therapeutic uses of marijuana or of specific chemicals in the marijuana plant for other diseases and conditions is supported by other components of NIH as is appropriate to their mission. For a complete listing of all projects funded by NIH examining the potential therapeutic benefits of cannabinoids, see the Therapeutic Cannabinoid Research category in the NIH Report database.

The vast majority of research proposals received and funded by NIH on therapeutic benefits of cannabinoids have examined individual cannabinoid chemicals or, in a few cases, marijuana leaves delivered through some means other than smoking. Research proposals submitted to any NIH Institute of Center (IC) to study therapeutic benefits of marijuana or one of its ingredients must meet the same accepted standards of scientific design as any other proposal and, on the basis of peer review, should meet public health significance and IC priorities to be competitive with other applications that qualify for funding. NIDA is a scientific, not a policy-making agency. The same is true for the NIH as a whole. NIDA's role is to conduct and support scientific research on drugs and drug abuse and to advise the public and policy-makers, such as Congress, the White House Office of the National Drug Control Policy, and the U.S. Drug Enforcement Administration on the results of that research -- with the goal of ensuring that the nation's drug policies are informed by science. That said, NIDA does closely watch legislative changes both nationally and at the state level and supports research that studies how changing drug policies -- for instance laws around recreational or therapeutic use of marijuana -- affect rates of substance use and related public health issues.

About Cannabis Science, Inc. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

These Celebrities are Cashing In on the Cannabis Industry

Un problema risolto per la politica .....

Il Centro Studi di confindustria, nel documento intitolato "LE SFIDE DELLA POLITICA ECONOMICA" riguardante gli scenari economici europei e raffrontandoli con i dati italiani, evidenzia una situazione drammatica e disastrosa.


Dal documento di confindustria: "A partire dal 2000 la dinamica del PIL in Italia è risultata inferiore a quella degli altri principali paesi dell’Euroarea."... " L’Italia, insieme alla Spagna, ha subito una doppia recessione (nel 2008-2009 e nel 2012-2014). Il PIL italiano è diminuito del 9,0% tra il 2007 e il 2014 e quello spagnolo del 7,6% (fino al 2013). Germania e Francia hanno, invece, continuato il recupero iniziato nel 2010, tant’è che nel 2014 i livelli di PIL delle due economie erano già superiori ai massimi pre-crisi, del 5,6% il tedesco e del 2,6% il francese."


La cosa peggiore è che la crisi ha eroso il potenziale economico italiano e la sua capacità di tornare a crescere riducendo la crescita potenziale italiana.


"Nel corso della crisi, naturalmente, la performance della produttività italiana ha risentito della caduta della domanda e dell’attività economica. Caduta così violenta da comportare perdita di capacità produttiva e abbassamento della crescita potenziale del PIL.
La crescita del PIL potenziale1 italiano era già molto bassa prima della crisi. La doppia recessione l’ha ulteriormente e notevolmente intaccata. La sua dinamica è così passata dall’1,1% nel 2000-2007 (allora era in linea con quella tedesca, ma molto inferiore a quella del
resto dell’Euroarea) al -0,5% tra 2008 e 2015 (Tabella B).
L’erosione della crescita potenziale nel corso della crisi si riflette anche nelle proiezioni sull’andamento del PIL italiano nel lungo periodo fatte dal Fondo monetario internazionale prima e dopo la crisi: nel World economic outlook del 2007 era prevista una variazione dell’1,2%; quest’anno si ferma al +0,7%."

In sintesi, tra il 2000 e il 2017, l'italia ha smesso di crescere e ha ridotto la sua capacità di generare, ricchezza, lavoro, benessere.

Se questi dati si incrociano con quelli dell'ISTAT riguardante i mercati illegali e più precisamente quelli legai al mercato della droga elaborati nel documento "I NUOVI CONTI NAZIONALI IN SEC 2010 Innovazioni e ricostruzione delle serie storiche (1995-2013)" risulta una analisi economica legata alla legalizzazione della cannabis ... allucinante.


Il rapporto evidenzia come, tra le attività illegali, la componente maggiore è rappresentata dal traffico di droga: "La componente più rilevante tra le tre attività illegali ora misurate dai conti nazionali riguarda la commercializzazione di droga, la quale, in termini di valore aggiunto, è valutata nel 2011 in 10,5 miliardi di euro", cioè lo 0,6% del pil 2011.






I dati sul traffico di droga, però, sono basati su stime; le stime in Italia valutano il mercato della cannabis attorno agli 8 miliardi di euro. Cioè circa lo 0,4% del pil annuo sul 2011.

Incrociando questi dati (la stima dello 0.4% del pil prodotto dalla cannabis), con i risultati di confindustria (che vedono una crescita del pil tra il 2000 e il 2017 dello 0,7 % complessivo) e moltiplicando la crescita del pil legato alla cannabis per gli anni dal 2000 al 2017, si avrebbe un risultato positivo del 6,8% (0,4%*17) contro una crescita "ufficiale dello 0,7% nello stesso arco di tempo.

Questa stima matematica, però, non tiene conto di alcuni importanti fattori. Per esempio di una industria legale che avrebbe potuto attrarre turismo, di nuove imprese legate alla cannabis nel settore dell'elettronica, elettrotecnica, delle energie, dell'agricoltura, dell'idraulica, dell'immobiliare, del farmaceutico, e altri settori indotti dalla crescita del mercato della cannabis.

La cosa che salta maggiormente all'occhio, e che nel confronto tra Spagna, Germania, Francia e Italia, proprio la Spagna, che vede nei cannabis social club, una forma di cannabis legale, è il paese con la migliore performance economica. Ovviamente, la performance economica spagnola, non è interamente spiegabile attraverso la presenza di una forma soft di tolleranza nei confronti del mercato della cannabis, ma sicuramente, la tolleranza nei confronti della cannabis, ha contributo positivamente ad una maggiore crescita. Risulta così anche evidente, l'impatto "moltiplicatore" di una tolleranza verso la cannabis, che vede nell'indotto di questo settore un fattore di crescita positivo da aggiungere alle stime ISTAT.

P.S.: La crescita del pil rappresenta la crescita media dei redditi dei lavoratori e dei profitti delle imprese. Con la cannabis illegale si danneggiano prima di tutto i non consumatori, che non vedono la possibilità di una crescita dei loro salari legati ad un miglior sviluppo economico.

How a U.S. Marijuana Company Helped Legalize MMJ in Mexico

JON HILTZ ON MAY 12TH, 2017 AT 12:51 PM | UPDATED: MAY 12TH, 2017 AT 12:52 PM

INTERNATIONAL NEWS

There are many people and companies who stand to benefit from the upcoming legalization of medical marijuana in Mexico. First and foremost, the benefactors will be patients who need cannabis treatment now.

Coming a close second are companies in the MMJ space who stand to make incredible gains from medical legalization, and right now, there is only one company in Mexico poised for a huge win. That corporation is the American firm Medical Marijuana Inc.

Medical Marijuana Inc. is the first publicly traded cannabis company in America. The corporation also started HempMeds Mexico, their distribution arm for CBD products in the Latin nation. They were the first and are currently the only legal supplier of cannabis-based products in Mexico.

Marijuana.com sat down with CEO Dr. Stuart Titus to discuss the future of cannabis in Mexico and the role his company will be playing.

It must be incredible to see marijuana traded as a public commodity, with you and I having grown up in the era of prohibition.

It’s been absolutely amazing. It’s been exciting to see the growth here in the U.S. but also some of the Canadian licensed producers and the companies raising tremendous amounts of capital.

As of April 28th, Mexico is one signature away from having legal medical cannabis, is that still the case?

That’s still the case as best we understand. Quite exciting. Obviously, President Peña Nieto has changed his opinion on cannabis-based products. I think, in large part, this is due to one of the families that we’ve been able to assist over the last year and a half.

This gentleman, Raul Elizalde, whose daughter Grace went from having these terrible epileptic seizures to now becoming virtually seizure-free. Raul has been a very forward spokesperson. President Peña Nieto has seen how well our products have been received in Mexico since February of 2016.

Your company has been a catalyst for helping the medical marijuana industry move forward in Mexico. Can you outline how that is the case?

We had been servicing a number of families in Brazil, and of course, there are epilepsy children in Mexico whose families saw the great success in Brazil. [So they]  petitioned the government to allow the products in Mexico.

The Mexican Government was very pro-CBD, but because of their unfortunate war on drugs and cartel violence, they were very anti-THC. Our products that we ship to Brazil have a trace of THC, 0.3 or less, but even trace amounts the government of Mexico was very cautious about. They challenged us to develop a fully THC-free version.

So we went to our laboratory facilities in the fall of 2015 and developed this fully THC-free version.

So this was the first-ever CBD oil allowed in Mexico?

Yes, this was the first. It was allowed February 1st, 2016. We are still the only legal cannabis-based product within Mexico today.

It’s fair to say that Medical Marijuana Inc. is poised to benefit greatly with this legalization news in Mexico.

We’re very excited about it because to date we have only been able to bring our [one product,] the THC-free version, into Mexico.

Have you spoken with the President or anyone in the Mexican government about moving forward?

Our President of Mexico Operations has spoken with President Peña Nieto. We’ve talked about moving forward in terms of education for doctors. Coming up towards the end of June I’ll be lecturing in front of about 150 doctors to help them get more familiar with not only CBD but medical cannabis.

---

More often than not, large corporations are dismissed for having a sole interest in their bottom line. But when speaking to Dr. Titus, you can hear the enthusiasm and passion he holds for his products, which help thousands of patients in desperate need.

Mexico is on the precipice of a whole new dimension of medicine which will help countless lives. It’s clear that the importance of this fact has not been lost on the individuals behind Medical Marijuana Inc.

Photo courtesy of Allie Beckett

Alaska's First Marijuana Industry Convention Showcases A Bright Future

Daily Dose Of Cannabis May Protect And Heal The Brain From Effects Of Aging

Janet Burns,
Opinions expressed by Forbes Contributors are their own.

Despite your average Shaggy and Scooby-style stereotypes, researchers believe that cannabis could actually help to sharpen our minds later in life.

Researchers at the University of Bonn and Hebrew University have discovered that low, regular doses of tetrahydrocannabinol (THC), one of the main active ingredients or cannabinoids found in marijuana, may help to keep our brains from 'slowing down' as we get older. Published today in the journal Nature Medicine, the German study revealed that while younger mice suffered a performance drop under the influence of THC, the psychoactive chemical gave older mice a considerable performance boost, even putting them on par with younger mice who'd abstained.

To test the chemical's effect on brains of different ages, researchers put mice that were two months, one year, and 18 months old on a daily regimen of THC over the course of a month. The mice were then tested on their abilities to recognize familiar objects, and to navigate a water maze in known and new configurations.

As has been similarly observed with humans, younger animals excelled at the tests when 'sober' but tended to struggle significantly under the influence of THC. "Mature" and "old" mice, on the other hand, struggled with tasks consistent to their brain age at first, but saw a huge increase in performance with THC infusions that brought their skill level up to young-mouse standards and continued for weeks afterward. Meanwhile, The Guardian reported, "None of the mice displayed the strange effects one might expect from doses of THC."

Overall, the results seem to support researchers' belief that the benefits for older mice are a result of stimulating the brain's endocannabinoid system, a biochemical pathway in both mice and human that grows less active over time. The scientists noted, "Together, these results reveal a profound,long-lasting improvement of cognitive performanceresulting from a low dose of THC treatment in mature andold animals."

The team plans to explore the potential impact of THC on older human brains with a clinical trial later this year, being one of few to focus on more aged subjects so far. Previous research with mice by the Universities of Bonn and Mainz also suggested that the brain's main cannabis receptor and neural pathways are closely related to brain health in later life, and seem to play a role in preventing brain degeneration when active.

Co-author Andras Bilkei-Gorzo told the Guardian, “If we can rejuvenate the brain so that everybody gets five to 10 more years without needing extra care then that is more than we could have imagined.”
Janet Burns covers tech, culture, and other fun stuff from Brooklyn, NY. She also hosts the cannabis news podcast The Toke.
Daily Dose Of Cannabis May Protect And Heal The Brain From Effects Of Aging

Greece May Soon Legalize Medicinal Cannabis

By

 Kerry Kolasa-Sikiaridi

 -

 Apr 23, 2017

The production of cannabis in Greece for the legal consumption of medicinal purposes may soon be passed in Parliament.

Health Minister Andreas Xanthos has stated that measures are underway to approve such a bill and that once approved, doctors will be able to prescribe medicinal cannabis, which would be packaged and produced in Greece.

Greece would be one of several countries in Europe to legalize cannabis for medicinal purposes as Austria, the Czech Republic, Finland, Germany, Italy, Portugal and Spain have already done so.

- See more at: http://greece.greekreporter.com/2017/04/23/greece-may-soon-legalize-medicinal-cannabis/#sthash.hELJuhRd.dpuf

Weed nuns grow and harvest cannabis in California

Legalizzare …ma quando? Incontro con i parlamentari dell’Intergruppo a Indica Sativa Trade

Le notizie di questi giorni, relative alla scoperta di una piantagione domotica di solo 6 piante di cannabis che tanto risalto ha avuto sui quotidiani della capitale e le reazioni di alcuni esponenti di Forza Italia, Lega e Milano Popolare nei confronti del Festival della Cannabis di Lambrate, ci fanno capire che nonostante l’impegno degli oltre 300 parlamentari che hanno firmato la pdl presentata dall’Intergruppo, nonostante le oltre 60.000 firme raccolte per iniziativa dei Radicali Italiani e nonostante, si stima, circa 5.000.000 di italiani usano consumare cannabis più o meno regolarmente, la stupida demonizzazione di questa benefica pianta non cessa e anzi sembra trovare sempre nuovo vigore nella falsa informazione.

E’ forse il caso, quindi, di capire meglio dov’è che stiamo sbagliando, se continua ad essere così difficile usare il buon senso per sconfiggere il pregiudizio ideologico, che sostiene da sempre la componente proibizionista e buona parte dell’opinione pubblica.

E’ probabile che abbiamo sbagliato qualcosa nella strategia iniziale, continuando a elencare tutte le relazioni della canapa con varie realtà discutibili, all’interno della richiesta di legalizzarne l’uso personale, senza mai riuscire a dare una panoramica generale dei vantaggi che la legalizzazione comporterebbe e dell’impegno civile che sostiene in varie direzioni.

Nei dibattiti parlamentari e tra l’opinione pubblica ormai è diffusa la convinzione che la legalizzazione sia esclusivamente una battaglia tra una concessione terapeutica per i pazienti affetti da patologie pesanti e una licenza all’autodistruzione di milioni di persone, a cui la legalizzazione porterebbe.

Dovremmo ora alzare il tiro e fare della battaglia per la legalizzazione una bandiera sotto la quale coagulare il consenso sociale, far capire che l’obiettivo è uno, ma gli avversari che vanno sconfitti raggiungendo quell’obiettivo sono tanti: gli interessi della criminalità in primis, ma anche quelli delle case farmaceutiche, delle imprese coinvolte nella deforestazione e di quelle che hanno interessi nel commercio e nella trasformazione del petrolio, impegnarsi quindi nella battaglia antiproibizionista significa quindi non solo difendere la dignità e la libertà di milioni di persone, ma anche assestare un colpo mortale agli interessi della criminalità, liberare chi ne ha bisogno dalla prepotenza e dal monopolio delle case farmaceutiche e difendere il nostro pianeta da uno sfruttamento incontrollato.

Per parlare di tutto questo e dello stato in cui versa la pdl presentata dall’Intergruppo Parlamentare, ASCIA e CIP, in collaborazione con gli organizzatori della Fiera, hanno invitato il Sen. Della Vedova (promotore dell’Intergruppo), Rita Bernardini (Presidente Onorario), il Sen. Airola e gli On. Ferraresi, Farina, Zaccagnini e Brignone per un confronto con le Associazioni, che si terrà sabato 13 maggio alle ore 16 in occasione della 4^ edizione di Indica Sativa Trade <http://www.indicasativatrade.com/>

ASCIA – www.ascia-web.org

CIP – www.canapainfopoint.it

Legalizzare …ma quando? Incontro con i parlamentari dell’Intergruppo a Indica Sativa Trade